Fifteen Additional Medications Included in Medicare Price Negotiation Process

Overview

The Trump administration announced 15 additional drugs subject to Medicare price negotiation, marking the first inclusion of physician-administered drugs under Part B. These negotiated prices will take effect in 2028 and aim to reduce costs for expensive medications, including several cancer and HIV treatments.

Background

Medicare price negotiation is a policy designed to lower drug costs for Medicare beneficiaries by allowing the government to negotiate prices directly with manufacturers. Previously, only retail drugs covered under Part D were eligible, but this is the first year physician-administered drugs under Part B are included. Some drugs, especially those in protected classes like cancer and HIV therapies, are expected to yield significant savings due to current rebate negotiation challenges. The program reflects a shift in drug pricing strategy under the Trump administration, despite political opposition.

Data Highlights

Key Findings

• Fifteen drugs were added to the Medicare price negotiation list, including the first physician-administered drugs under Part B.
• Negotiated prices will be implemented starting in 2028.
• Several included drugs are for cancer and HIV, which are protected classes under Medicare and may yield substantial savings.
• Physician-administered drugs pose data challenges due to incomplete pricing information from Medicare Advantage plans.
• The list includes drugs for autoimmune diseases, cardiovascular conditions, schizophrenia, and asthma.
• The Trump administration emphasized targeting the most expensive Medicare drugs to negotiate fair prices.

Clinical Implications

Clinicians should be aware that drug costs for these 15 medications may decrease starting in 2028 due to Medicare negotiations, potentially improving patient access and adherence. The inclusion of physician-administered drugs may also impact treatment planning and reimbursement processes. Awareness of these changes can aid in patient counseling regarding medication affordability.

Conclusion

The expansion of Medicare price negotiation to include physician-administered drugs represents a significant policy development aimed at reducing drug costs for beneficiaries. This initiative may lead to broader access and financial relief for patients requiring high-cost therapies.

References

1. Centers for Medicare and Medicaid Services Press Release